A Phase IIIb, Single-arm, Open-label Multicentre Study of Olaparib Monotherapy in the Treatment of HER2-ve Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.

Trial Profile

A Phase IIIb, Single-arm, Open-label Multicentre Study of Olaparib Monotherapy in the Treatment of HER2-ve Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 01 Apr 2018

At a glance

  • Drugs Olaparib (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms LUCY
  • Sponsors AstraZeneca
  • Most Recent Events

    • 23 Feb 2018 Planned End Date changed from 30 Jun 2020 to 29 Nov 2020.
    • 23 Feb 2018 Planned primary completion date changed from 30 Jun 2020 to 29 Nov 2020.
    • 23 Jan 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top